Ambrx Biopharma Shares Outstanding 2020-2022 | AMAM

Ambrx Biopharma shares outstanding from 2020 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Ambrx Biopharma Annual Shares Outstanding
(Millions of Shares)
2021 20
2020 17
2019 19
Ambrx Biopharma Quarterly Shares Outstanding
(Millions of Shares)
2022-06-30
2021-12-31 143
2021-06-30
2020-12-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.019B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.688B 10.41
GSK (GSK) United Kingdom $70.345B 8.82
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.600B 0.00
Arcus Biosciences (RCUS) United States $2.547B 38.23
Biohaven (BHVN) United States $1.078B 0.00
Emergent Biosolutions (EBS) United States $0.614B 4.82
Zymeworks (ZYME) Canada $0.486B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.281B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.074B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00